Repetitive low-dose tissue plasminogen activator for the clearance of experimental vitreous hemorrhage

Woog-Ki MIN; Yong-Baek KIM; Byung-Heon AHN; Geun-Hae SEONG.
Korean Journal of Ophthalmology ; : 45-48, 1994.
Artículo en Inglés | WPRIM | ID: wpr-175243

Documentos relacionados

  1. Repetitive low-dose tissue plasminogen activator for the clearance of experimental vitreous hemorrhage.
  2. Intravitreal tissue plasminogen activator treatment of experimental vitreous hemorrhage.
  3. Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
  4. Intravitreal tPA and SF6 promote clearing of premacular subhyaloid hemorrhages in shaken and battered baby syndrome.
  5. VITRECTOMY WITH SUBRETINAL INJECTION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR FOR SUBMACULAR HEMORRHAGE WITH OR WITHOUT VITREOUS HEMORRHAGE.
  6. Natural evolution of experimental vitreous hemorrhage and effects of corticosteroids on its course.
  7. The role of intravitreal bevacizumab in experimental posterior penetrating eye injury.
  8. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.
  9. EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL.
  10. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage.